Target intelligence / Profile preview

Cys-loop receptor (CLR)

Target
CLR
Molecular classification
Ion channel, Ligand-gated ion channel, Receptor
01

Overview

Cys-loop receptors are a major superfamily of pentameric ligand-gated ion channels (pLGICs) that play a fundamental role in fast excitatory and inhibitory synaptic transmission throughout the central and peripheral nervous systems (IUPHAR/BPS Guide to Pharmacology). They are defined by a characteristic 13-amino acid loop in the extracellular N-terminal domain, closed by a disulfide bridge between two cysteine residues (PubMed: 25003714). This superfamily includes the nicotinic acetylcholine receptors (nAChR), gamma-aminobutyric acid type A receptors (GABA-A), glycine receptors (GlyR), and the serotonin type 3 receptor (5-HT3R) (UniProt). These receptors function as molecular switches that convert chemical signals—neurotransmitters—into electrical signals by opening an intrinsic ion-conducting pore upon ligand binding (PubMed: 15816835). Because of their central role in neural signaling, they are critical therapeutic targets for a variety of conditions, including anxiety, insomnia, epilepsy, and chemotherapy-induced nausea (StatPearls). Drugs targeting these receptors range from full agonists and antagonists to positive and negative allosteric modulators, which fine-tune channel activity (PubMed: 21496447).

Other names
Pentameric ligand-gated ion channelpLGICCys-loop ligand-gated ion channel superfamily
02

Mechanism of action

Agonism, antagonism, and allosteric modulation of ion channel opening to regulate cation or anion conductance across the cell membrane (PubMed: 15816835).

03

Biological functions

Fast synaptic transmissionSignal transductionNeurotransmissionIon homeostasisMembrane potential regulation
04

Disease associations

EpilepsyAlzheimer's diseaseParkinson's diseaseSchizophreniaAnxietyDepressionAddictionMyasthenia gravisChronic painNausea and vomiting
05

Safety considerations

SedationRespiratory depressionPhysical dependenceWithdrawal symptomsCognitive impairmentSeizure risk
06

Interacting drugs

Nicotine

11 more in the full profile.

07

Biomarkers

Receptor occupancy (PET/SPECT imaging)Genetic variants (e.g., CHRNA4, GABRA1, GABRG2)CSF neurotransmitter levels

Beyond the preview

Go deeper on Cys-loop receptor (CLR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cys-loop receptor (CLR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call